BCM
VIGL

Bridgeway Capital Management’s Vigil Neuroscience VIGL Stock Holding History

Bridgeway Capital Management’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-79,864
Closed -$142K – 1272
2025
Q1 		$142K Sell
79,864
-20,200
-20% -$45.3K ﹤0.01% 987
2024
Q4 		$170K Sell
100,064
-5,000
-5% -$14.8K ﹤0.01% 1036
2024
Q3 		$357K Buy
105,064
+25,000
+31% +$92.6K 0.01% 941
2024
Q2 		$320K Buy
80,064
+22,100
+38% +$75.6K 0.01% 961
2024
Q1 		$198K Sell
57,964
-75,000
-56% -$234K ﹤0.01% 1112
2023
Q4 		$449K Buy
+132,964
New +$684K 0.01% 967

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Bridgeway Capital Management's VIGL Position: Q2 2025 in Review

Bridgeway Capital Management sold out of Vigil Neuroscience (VIGL) in Q2 2025, closing a stake of 79,864 shares — an estimated $142K sold.

Bridgeway Capital Management first reported a position in VIGL in Q4 2023 and held it in 6 quarters. The position peaked at $449K in Q4 2023. 78 funds tracked by Wall St. Rank hold VIGL as of Q2 2025.

  • Bridgeway Capital Management reported no remaining Vigil Neuroscience position as of Q2 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 79,864 Vigil Neuroscience shares in Q2 2025, an estimated $142K.
  • Bridgeway Capital Management first reported a position in Vigil Neuroscience in Q4 2023 and held it in 6 quarters.
  • Bridgeway Capital Management's Vigil Neuroscience position peaked at $449K in Q4 2023.
  • 78 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2025.

Based on Bridgeway Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.